Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TERNS PHARMACEUTICALS, INC.

(TERN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Terns Pharmaceuticals : Starts Patient Dosing in Phase 1b Trial of Liver Disease Treatment

06/24/2021 | 04:27pm EDT


ę MT Newswires 2021
All news about TERNS PHARMACEUTICALS, INC.
09/20TERNS PHARMACEUTICALS, INC.(NASDAQGS : TERN) dropped from S&P Global BMI Index
CI
09/08TERNS PHARMACEUTICALS : Completes Patient Enrollment in Part 1 of Phase 1b Trial of Potent..
MT
09/08TERNS PHARMACEUTICALS : Completes Part 1 Enrollment of AVIATION Phase 1b NASH Clinical Tri..
AQ
09/08Terns Pharmaceuticals, Inc. Completes Part 1 Enrollment of Aviation Phase 1b NASH Clini..
CI
09/02TERNS PHARMACEUTICALS : to Present at Upcoming Investor Conferences
AQ
08/17TERNS PHARMACEUTICALS' : Q2 Loss Narrows, Operating Expenses Increase; Shares Climb
MT
08/16TERNS PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Financial Sta..
AQ
08/16TERNS PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Re..
AQ
08/16TERNS PHARMACEUTICALS : Reports Second Quarter 2021 Financial Results and Corporate Highli..
PU
08/16TERNS PHARMACEUTICALS : Reports Second Quarter 2021 Financial Results and Corporate Highli..
AQ
More news
Analyst Recommendations on TERNS PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -56,2 M - -
Net cash 2021 81,5 M - -
P/E ratio 2021 -4,35x
Yield 2021 -
Capitalization 271 M 271 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 30
Free-Float 92,2%
Chart TERNS PHARMACEUTICALS, INC.
Duration : Period :
Terns Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TERNS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 10,78 $
Average target price 20,00 $
Spread / Average Target 85,5%
EPS Revisions
Managers and Directors
Senthil Sundaram Chief Executive Officer & Director
Erin Quirk President & Chief Medical Officer
Mark J. Vignola Chief Financial Officer & Treasurer
David A. Fellows Chairman
Weidong Zhong Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
TERNS PHARMACEUTICALS, INC.0.00%271
MODERNA, INC.321.86%175 199
LONZA GROUP AG33.09%60 866
IQVIA HOLDINGS INC.44.97%49 103
CELLTRION, INC.-23.26%31 708
SEAGEN INC.-3.41%30 021